Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873195 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v7, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 10
- Study locations
NCT02873195 is a Phase 2 study of Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v7 that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 133 participants, above the 83-participant average among 22 other Metastatic Colorectal Carcinoma trials with a reported enrollment target (60% higher). The trial reports 10 study locations across 8 states.
The verdict
NCT02873195, a Phase 2 study of Metastatic Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v7, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 10
- Study locations
Study Summary
This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with capecitabine and bevacizumab may be a better way in treating colorectal cancer.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Atezolizumab
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
Study Locations (10)
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic in Arizona - Scottsdale
California
- City of Hope Comprehensive Cancer Center - Duarte
- USC / Norris Comprehensive Cancer Center - Los Angeles
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
New York
- Roswell Park Cancer Institute - Buffalo
North Carolina
- Duke University Medical Center - Durham
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873195
The ClinicalTrials.gov registry entry for NCT02873195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 22 other Metastatic Colorectal Carcinoma trials with a reported enrollment target (60% higher). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Metastatic Colorectal Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT02873195 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02873195 about?
NCT02873195 is a clinical study titled "Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer". This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizuma...
What is the current status of trial NCT02873195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2017-07-07. Estimated completion is 2023-12-01.
What conditions does trial NCT02873195 study?
This clinical trial studies the following conditions: Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Recurrent Colorectal Carcinoma.
What interventions are being tested in trial NCT02873195?
The interventions under investigation include: Capecitabine (DRUG), Atezolizumab (DRUG), Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02873195?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02873195 being conducted?
This trial has 10 study locations across Arizona, California, Georgia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RECRUITING · Phase 1
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Colorectal Carcinoma
All registered trials for this condition
Stage IV Colorectal Cancer AJCC v7
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.